CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 8, 2024
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 –
